US Earnings Financial Results SEC Filings — May 12, 2026

12-05-2026

VenHub Global reported a sharply declining revenue of $67,836 for Q1 2026, down 86% YoY from $500,000, with gross profit falling 98% to $3,689, though operating expenses decreased 52% to $4.5M, narrowing the operating loss. However, massive non-cash interest expense of $11.2M led to a widened net loss of $16.6M versus $9.3M YoY. Balance sheet strengthened significantly with cash surging 6,375% QoQ to $5.8M and stockholders' equity turning positive at $3.3M from a $10.3M deficit, fueled by $13.3M in financing inflows from warrants and stock issuances.

• · Common shares issued increased by 10,033,501 during Q1 2026, including 7,700,000 from warrant issuance and 2,000,000 for note extension.
• · Convertible debt at fair value reduced to $0 from $4,576,949 QoQ.
• · Related party loan payable increased to $2,100,000 from $1,000,000 QoQ.
• · Net cash used in operating activities worsened to $7.5M from $1.4M YoY.

12-05-2026

Verde Clean Fuels, Inc. reported an improved net loss of $2,393 thousand for the three months ended March 31, 2026, compared to $2,704 thousand in the prior year period, driven by lower general and administrative expenses of $2,673 thousand (down 10.8% YoY) and slightly reduced R&D expenses. However, the company continued to incur operating losses and used $2,617 thousand in cash from operations (improved from $3,702 thousand YoY), resulting in a net cash decrease of $2,934 thousand and ending cash of $54,381 thousand. Stockholders' equity declined slightly to $56,338 thousand from $58,135 thousand at December 31, 2025.

• · Loss per share of Class A common stock improved to $(0.05) from $(0.08) YoY.
• · Net cash used in investing activities increased to $317 thousand from $12 thousand YoY due to higher additions to property, plant and equipment.
• · No cash flows from financing activities in Q1 2026, compared to $49,950 thousand provided in Q1 2025 from issuance to Cottonmouth.

12-05-2026

For the quarter ended March 31, 2026, Nuveen Churchill Private Capital Income Fund's total assets grew 13% QoQ to $2,513,978 from $2,226,562, with net assets increasing 4% to $1,447,407, supported by $108M in share issuances but offset by $30,703 in distributions and $41,911 payable for repurchases. Investment income rose 19% YoY to $50,745 and net investment income increased 14% to $29,694; however, net realized and unrealized losses on investments widened to $(17,875) from $(10,213), driving a 25% YoY decline in net increase in net assets from operations to $11,819 versus $15,848. Secured borrowings expanded 25% QoQ to $984,302 amid $233,000 in new proceeds.

• · Net realized loss on investments of $(2,022) for the quarter versus gain of $212 YoY.
• · Net change in unrealized depreciation of $(15,853) versus $(10,425) YoY.
• · Cash flows from operating activities used $(247,843) versus $(100,865) YoY.
• · Weighted average Class I shares outstanding 57,166,472 versus 34,528,300 YoY.
• · Per share net investment income declined YoY across classes: Class I from $0.72 to $0.50.

12-05-2026

For the three months ended March 31, 2026, New Mountain Net Lease Trust reported total revenues of $30,012, up 11% YoY from $27,051, driven by higher rental revenue, with net income rising 14% YoY to $5,999 and net cash from operating activities increasing 11% to $14,620. However, total expenses surged 27% YoY to $14,512, investments in real estate declined 0.7% QoQ to $1,285,495 from $1,294,008, and earnings per share decreased for Class F (to $0.11 from $0.12 YoY) and Class I (to $0.07 from $0.09 YoY). Total shareholders' equity grew 17% QoQ to $466,202, bolstered by $78,589 in common shares issued, while mortgage notes and credit facility decreased 7% QoQ to $862,943.

• · Earnings less than distributions worsened to ($145,181) as of March 31, 2026 from ($135,177) at December 31, 2025.
• · Distributions declared at $0.425 gross per share, totaling $14,646 paid.
• · Proceeds from common shares issued: $78,550 (net of offering costs).

12-05-2026

Sound Financial Bancorp reported net income of $1,576 thousand for the three months ended March 31, 2026, up 35% YoY from $1,167 thousand, with net interest income increasing 12% to $9,047 thousand amid higher loan interest income. However, noninterest income fell 17% to $910 thousand due to lower service charges, BOLI earnings, and mortgage servicing income, while provision for credit losses flipped to an expense of $123 thousand from a $203 thousand release. Total assets grew 1.8% QoQ to $1,112,051 thousand as of March 31, 2026, driven by 1.8% loan portfolio growth and 2.1% deposit increase.

• · Earnings per share (basic and diluted): $0.61 for Q1 2026 vs. $0.45 for Q1 2025
• · Cash dividends paid: $0.21 per share in Q1 2026 (total $541 thousand) vs. $0.19 per share in Q1 2025 (total $487 thousand)
• · Net cash used in investing activities: $21,062 thousand in Q1 2026 vs. provided $13,919 thousand in Q1 2025, primarily due to $16,019 thousand net increase in loans
• · Allowance for credit losses on loans: $8,635 thousand as of March 31, 2026 (up from $8,605 thousand at Dec 31, 2025)

12-05-2026

Public Co Management Corp (PCMC) reported revenues of $0 for the three months ended March 31, 2026, flat YoY, but net loss widened significantly to $74,107 from $21,155, driven by G&A expenses surging 313% to $76,588. For the six months ended March 31, 2026, net loss increased to $91,130 from $41,492 YoY, with cash balance plummeting to $15,052 from $234,405 at September 30, 2025 amid operating cash usage and a $130,000 investing outflow. However, total liabilities decreased to $313,343 from $474,803, aided by a $168,545 non-cash offset of related-party note receivable against payables.

• · Net cash used in operating activities for six months ended Mar 31, 2026: $89,353 (vs $80,318 in 2025, increased usage)
• · Stockholders’ deficit at Mar 31, 2026: $(298,291) (worsened from $(207,161) at Sep 30, 2025)
• · Note payable – related party at Mar 31, 2026: $279,484 (down from $350,000 at Sep 30, 2025)
• · Accumulated deficit at Mar 31, 2026: $(5,827,307) (vs $(5,736,177) at Sep 30, 2025)

12-05-2026

Venture Global reported Q1 2026 revenue of $4,599 million, up 59% YoY from $2,894 million, primarily driven by LNG revenue increasing 59% to $4,575 million. Net income attributable to common stockholders rose 23% to $488 million, with income from operations up 7% to $1,151 million. However, cost of sales more than doubled to $2,784 million, total operating expenses surged 90% to $3,448 million, and net cash from operating activities declined 32% to $763 million amid higher working capital changes.

• · Calcasieu Project: Operating; Plaquemines Project: Construction and Commissioning; CP2 Project: Construction; others in Development.
• · Basic EPS $0.20 in Q1 2026 vs $0.17 in Q1 2025.
• · Dividends declared on common stock $0.02 per share, totaling $45 million.
• · Net cash used by investing activities $2,998 million in Q1 2026 vs $3,470 million in Q1 2025.
• · Current restricted cash increased to $335 million from $195 million at Dec 31, 2025.

12-05-2026

Rocket Companies reported Q1 2026 net revenue of $2,941 million, up 167% YoY from $1,101 million, driven by gain on loan sales rising 78% to $1,376 million and loan servicing income turning positive at $598 million from a $48 million loss. Net income attributable to Rocket reached $297 million versus a $10 million loss in Q1 2025, with EPS of $0.10. However, total assets declined 2% QoQ to $59,439 million, mortgage loans held for sale fell 10% QoQ to $13,928 million, and change in fair value of MSRs remained negative at $485 million.

• · Operating cash flow improved to $1,857 million in Q1 2026 from ($796) million in Q1 2025.
• · Secured financing decreased to $15,882 million as of March 31, 2026 from $17,936 million at December 31, 2025.
• · Class A common stock shares outstanding: 978,704,853 as of March 31, 2026.

12-05-2026

Ducommun Inc reported robust Q1 2026 financial results with net revenues increasing 8.6% YoY to $209,022 from $192,481, gross profit up 11.5% to $56,233, and operating income surging 216% to $15,720 driven by a 10% reduction in SG&A expenses to $40,513 and absence of restructuring charges. Net income rose sharply 607% to $9,916 ($0.66 basic EPS) from $1,402 ($0.09), while cash flow from operations improved to $11,239 from $771. However, cash and equivalents declined 14% QoQ to $39,103 from $45,289, reflecting increases in accounts receivable and inventories alongside financing outflows.

• · Prior period financials for three months ended March 29, 2025 are as restated.
• · Weighted-average basic shares outstanding increased to 15,044 from 14,856 YoY.
• · Capex (purchases of property and equipment) decreased to $2,936 from $4,815 YoY.

12-05-2026

Unicycive Therapeutics reported a net loss of $12,823 thousand for the three months ended March 31, 2026, compared to net income of $570 thousand in the prior year period, driven by a $4,780 thousand loss on change in fair value of warrant liability versus an $8,348 thousand gain last year, while total operating expenses rose 5.6% YoY to $8,437 thousand with G&A up 17% despite R&D down 26%. Cash and equivalents increased to $37,371 thousand from $29,198 thousand at year-end, supported by $19,569 thousand net financing proceeds, and operating cash use improved to $6,241 thousand from $8,903 thousand. Stockholders' equity grew to $37,704 thousand from $30,197 thousand, though accumulated deficit widened to $140,648 thousand.

• · Warrant liability increased to $21,695 thousand from $16,915 thousand.
• · Weighted-average basic shares outstanding: 23,908,153 for Q1 2026 vs 11,681,881 for Q1 2025.
• · Issuance of 3,123,537 common shares for $19,566 thousand net proceeds in Q1 2026.
• · Marketable securities increased to $17,215 thousand from $12,071 thousand.

12-05-2026

Ampco-Pittsburgh reported total net sales of $108,327 thousand for Q1 2026, up 3.9% YoY from $104,265 thousand, driven by higher net sales and related party sales. However, income from operations fell 33.5% to $2,562 thousand due to higher costs of products sold, a deconsolidation charge, and lower other income, resulting in a net loss attributable to common shareholders of $867 thousand versus $1,142 thousand profit in Q1 2025. Operating cash flow improved significantly to $1,647 thousand from a $5,280 thousand outflow, though cash and equivalents declined to $9,226 thousand from $10,703 thousand QoQ.

• · Trade receivables increased to $93,581 thousand from $78,981 thousand QoQ.
• · Asbestos liability decreased to $192,969 thousand ($28,000 current + $164,969 noncurrent) from $198,332 thousand QoQ.
• · Depreciation and amortization decreased to $4,258 thousand from $4,636 thousand YoY.
• · Weighted-average basic shares outstanding: 20,237 (Q1 2026) vs 19,980 (Q1 2025).

12-05-2026

C4 Therapeutics reported revenue from collaboration agreements of $6,152 for Q1 2026, down 15% YoY from $7,238, while research and development expenses decreased 9% to $24,606 and general and administrative expenses remained flat at $9,331, leading to total operating expenses of $33,937 (down 7% YoY). Net loss improved to $25,129 from $26,322 YoY. However, cash and cash equivalents declined 18% QoQ to $61,274 from $74,603, with net cash used in operations at $29,944 and total assets down 8% QoQ to $328,861.

• · Issued 6,187,000 shares of common stock upon exercise of warrants.
• · Net cash provided by investing activities $16,153 in Q1 2026, down from $29,125 YoY.
• · Stock-based compensation expense $2,671 in Q1 2026, down from $5,507 YoY.
• · Unrealized loss on marketable securities $372 in Q1 2026.

12-05-2026

Madison Air Solutions Corp reported net sales of $923.7M for the three months ended March 31, 2026, up 33.8% YoY from $690.4M, primarily driven by acquisitions (21.2% impact) with overall organic growth slowing to 11.7% from 19.2%; Commercial organic growth was solid at 17.2% (down from 29.5%) while Residential organic declined 1.9% (vs -1.0% prior). Gross profit margin improved to 37.2% and adjusted net income rose to $92.5M from $70.0M, but reported net income dipped to $43.0M from $46.2M and FCF remained flat at $50.4M.

• · Net cash flows used in investing activities Q1 2026: $(8.1)M vs $4.5M provided in Q1 2025
• · Total net change in cash and cash equivalents Q1 2026: $20.2M vs $75.4M in Q1 2025
• · Pro Forma net sales three months ended March 31, 2025: $130.5M with Adjusted EBITDA margin of 25.7%

12-05-2026

Ovid Therapeutics reported no revenue in Q1 2026 compared to $0.1M in Q1 2025, with net loss widening to $17.0M from $10.2M YoY due to R&D expenses surging 68% to $11.2M and total operating expenses up 41% to $17.8M. However, financing activities provided $89.0M net proceeds from PIPE, ATM, and warrant exercises, boosting cash and equivalents to $94.1M from $13.2M at year-end 2025 and total assets to $225.6M (up 50% QoQ). Operating cash use increased to $13.9M from $10.3M YoY, reflecting higher burn rate.

• · Weighted-average common shares outstanding: 136,171,393 in Q1 2026 (vs 71,045,265 in Q1 2025).
• · Stock-based compensation expense: $1,046 thousand in Q1 2026 (down from $1,284 thousand YoY).
• · Net cash provided by investing activities: $5,950 thousand in Q1 2026 (up slightly from $5,102 thousand YoY).

12-05-2026

Sleep Number Corp reported net sales of $318,987 thousand for the three months ended April 4, 2026, down 19.1% YoY from $393,261 thousand, resulting in an operating loss of $36,856 thousand versus a $1,850 thousand profit in the prior year. The net loss widened to $50,297 thousand ($2.19 per share) from $8,646 thousand ($0.38 per share), driven by lower gross profit and higher restructuring costs, though sales and marketing expenses declined 15% and R&D expenses fell 51%. Total assets decreased to $641,008 thousand QoQ while borrowings under credit facility rose to $605,600 thousand.

• · Net cash used in operating activities increased to $7,751 thousand from $2,626 thousand YoY.
• · Restructuring costs rose to $21,736 thousand from $60 thousand YoY.
• · Weighted-average shares basic and diluted: 22,991 thousand in Q1 2026 vs. 22,706 thousand in Q1 2025.
• · Future amortization of definite-lived intangible assets totals $688 thousand.

12-05-2026

Passage Bio, Inc. (PASG) reported a narrowed net loss of $7,559 thousand for the three months ended March 31, 2026, compared to $15,405 thousand in the prior year period, driven by lower research and development expenses ($4,093 thousand vs. $7,737 thousand), lower general and administrative expenses ($4,787 thousand vs. $6,085 thousand), absence of impairment charges, and a $633 thousand net gain on lease termination. However, the company continued to burn cash with $12,987 thousand used in operating activities, resulting in cash and cash equivalents declining to $33,336 thousand from $46,303 thousand at December 31, 2025, and total assets falling to $36,462 thousand from $62,281 thousand. Stockholders' equity decreased to $11,752 thousand from $18,755 thousand amid the ongoing accumulated deficit widening to $712,316 thousand.

• · Loss from operations improved to $8,247 thousand in Q1 2026 from $16,459 thousand in Q1 2025.
• · Operating lease liabilities decreased significantly QoQ to $5,755 thousand total ($1,149 thousand current + $4,606 thousand noncurrent) from $24,010 thousand.
• · Property and equipment, net declined to $826 thousand from $4,107 thousand QoQ.
• · Weighted average common shares outstanding: 3,205,866 in Q1 2026 vs. 3,163,914 in Q1 2025.
• · Net loss per share: $(2.36) basic and diluted in Q1 2026 vs. $(4.87) in Q1 2025.

12-05-2026

Via Transportation reported Q1 2026 revenue of $127,434, up 29.2% YoY from $98,642, with gross profit increasing 25.7% to $50,055. However, operating expenses rose 29.1% to $73,639, resulting in a wider operating loss of $(23,584) versus $(17,224) and net loss of $(20,149) compared to $(16,317) a year ago. Cash used in operating activities deteriorated sharply to $(21,197) from $(5,596), ending with $349,376 in cash after a $22,709 QoQ decline.

• · Basic and diluted net loss per share improved to $(0.25) from $(1.28) YoY due to higher share count.
• · Comprehensive loss of $(22,170) in Q1 2026 versus $(12,985) in Q1 2025.
• · Current liabilities decreased QoQ to $90,624 from $94,235.
• · Net cash used in investing activities $2,281 in Q1 2026.

12-05-2026

Prelude Therapeutics Inc reported first-quarter revenue of $4,580 thousand in Q1 2026, up from $0 in Q1 2025 due to recognition of deferred revenue, while operating expenses fell sharply YoY with R&D down 53% to $13,601 thousand and G&A down 11% to $5,156 thousand, narrowing net loss to $10,385 thousand from $32,085 thousand. However, the company continued to burn cash with net cash used in operating activities at $21,685 thousand, leading to a QoQ decline in cash and equivalents to $21,756 thousand from $35,256 thousand and total assets to $119,642 thousand from $141,315 thousand.

• · Deferred revenue decreased to $30,952 thousand as of March 31, 2026 from $33,734 thousand as of December 31, 2025.
• · Stock-based compensation expense was $2,000 thousand in Q1 2026, down from $3,832 thousand in Q1 2025.
• · Other income, net increased to $3,792 thousand in Q1 2026 from $2,521 thousand in Q1 2025.

12-05-2026

Neuraxis reported strong Net Sales growth of 79.5% YoY to $1,607,883 for Q1 2026, driven by higher gross profit of $1,389,517 (up 83.8% YoY), while operating loss narrowed to $(1,740,679) from $(2,295,098) due to lower G&A and R&D expenses. However, selling expenses rose 64.8% YoY to $824,336, and the company still posted a net loss of $(1,761,432), with cash used in operations at $(1,229,757) albeit improved from prior year. Cash position strengthened to $7,078,659, up from $4,965,072 at year-end, bolstered by $3.3M in financing from stock issuances.

• · Cash used in operating activities improved to $(1,229,757) from $(1,603,655) YoY.
• · Warrant liabilities increased to $48,306 from $16,800 QoQ.
• · Basic and diluted loss per share improved to $(0.18) from $(0.33) YoY.

12-05-2026

Olema Pharmaceuticals reported a widened net loss of $53.1 million for Q1 2026, up 75% YoY from $30.4 million, driven by R&D expenses rising 61% to $49.2 million and G&A expenses more than doubling to $8.8 million. However, the company bolstered its liquidity with $41.9 million raised via at-the-market offering and stock option exercises, increasing cash and equivalents to $52.5 million (up from $48.3 million at year-end) alongside $452.8 million in marketable securities. Total cash, cash equivalents, and marketable securities stood at approximately $505.3 million as of March 31, 2026.

• · Net cash used in operating activities increased slightly to $46.0 million in Q1 2026 from $44.0 million in Q1 2025.
• · Unrealized losses on marketable securities totaled $608 thousand as of March 31, 2026, compared to $40 thousand as of December 31, 2025.
• · Stock-based compensation expense rose to $10.1 million in Q1 2026 from $4.4 million in Q1 2025.

12-05-2026

Sionna Therapeutics reported a widened net loss of $26,779 thousand for the three months ended March 31, 2026, up 62% YoY from $16,482 thousand, driven by research and development expenses rising 39% to $18,963 thousand and general and administrative expenses surging 78% to $10,636 thousand. Cash and cash equivalents increased 8% QoQ to $63,324 thousand, supported by net cash provided by investing activities of $24,820 thousand, however total assets declined 6% to $305,039 thousand and net cash used in operating activities grew 34% YoY to $21,840 thousand. Stockholders' equity decreased to $288,208 thousand from $306,833 thousand at December 31, 2025.

• · Interest income decreased to $2,820 thousand from $3,000 thousand YoY.
• · Weighted-average common shares outstanding increased to 44,921,984 from 26,596,059 YoY.
• · Unrealized loss on marketable securities of $624 thousand in Q1 2026 vs $67 thousand in Q1 2025.
• · Stock-based compensation expense rose to $6,553 thousand from $2,094 thousand YoY.

12-05-2026

Vestis Corp's Q2 FY26 revenue declined 0.9% YoY to $659.4M from $665.2M, while six-month revenue fell 1.9% YoY to $1,323M. However, operating income swung to a $26.8M profit from an $8.6M loss in Q2 and improved to $43.4M for six months from $21.8M, driven by sharp SG&A reductions; net loss narrowed significantly to $3.8M for six months from $27.0M YoY. Operating cash flow surged to $95.9M for six months from $10.4M, with cash rising to $50.3M and long-term debt declining to $1,115M.

• · Total assets decreased to $2,873M from $2,907M QoQ.
• · SG&A expenses dropped 24% YoY to $112.3M in Q2 from $147.9M.
• · Cost of services declined 0.85% YoY to $485.8M in Q2.

12-05-2026

Longduoduo Co Ltd reported sharply declining results for the three and nine months ended March 31, 2026, with total revenue dropping 76% YoY to $187,392 in Q3 and 64% YoY to $1,191,421 for the nine-month period, shifting from a prior-year nine-month profit of $325,775 to a net loss of $575,434. Operating cash flow turned negative at $(437,881) from $93,150 YoY, leading to a $417,840 cash reduction and total assets falling to $1,748,643 from $2,126,496 at June 30, 2025. Total liabilities rose to $957,123 amid higher deferred revenue and lease liabilities.

• · Service revenue declined sharply to $1,350 (three months) and $11,059 (nine months) from $28,724 and $117,640 YoY.
• · Commission revenue fell to $186,042 (three months) and $1,180,362 (nine months) from $748,996 and $3,204,647 YoY.
• · Selling, general and administrative expenses increased to $381,498 (three months) and $1,737,153 (nine months) from $876,095 and $2,819,107 YoY for nine months but decreased in three months period.
• · 10,020 shares issued for acquisition of LDD Technology Limited on February 19, 2025.

12-05-2026

Achieve Life Sciences reported a net loss of $10,168 thousand for Q1 2026, an improvement from $12,827 thousand YoY due to sharply lower R&D expenses ($3,292 thousand vs $7,097 thousand), though G&A expenses rose to $7,171 thousand from $5,797 thousand. Cash and equivalents increased to $28,078 thousand QoQ from $20,929 thousand amid reduced operating cash burn of $6,932 thousand (vs $11,088 thousand YoY), but total assets declined to $33,105 thousand from $41,790 thousand at year-end, driven by lower marketable securities, and stockholders' equity fell to $10,678 thousand. Operating cash flow improved significantly, supported by marketable securities maturities providing $14,276 thousand net inflow.

• · Convertible debt totaled $14,901 thousand as of March 31, 2026 ($5,579 thousand current, $9,322 thousand non-current).
• · Marketable securities declined to $1,191 thousand from $15,475 thousand QoQ.
• · Weighted average shares for EPS computation: 53,381,989 in Q1 2026 vs 34,685,072 in Q1 2025.
• · Basic and diluted net loss per share: $(0.19) in Q1 2026 vs $(0.37) in Q1 2025.

12-05-2026

SAB Biotherapeutics reported a widened net loss of $18,868,885 for Q1 2026 compared to $5,196,773 in Q1 2025, driven by research and development expenses increasing 75% to $13,397,977 and general and administrative expenses surging 112% to $6,599,759. However, the company bolstered its balance sheet via a March 2026 public offering and related financings raising $89,921,121 in net proceeds, lifting cash and equivalents to $20,519,724 from $10,502,680 QoQ and total assets to $248,470,498 from $172,809,969. Operating cash use intensified to $14,271,130 from $7,797,217 YoY amid higher spending.

• · Warrant liabilities increased to $6,117,586 from $5,635,112 QoQ.
• · Stock-based compensation expense rose to $5,459,911 from $612,951 YoY.
• · Common shares outstanding increased from 47,609,899 to 75,744,576 QoQ due to public offering and conversions.
• · Loss per common share improved to $(0.35) from $(0.56) YoY despite higher loss, due to increased shares.

12-05-2026

Sagimet Biosciences Inc. reported a reduced net loss of $10.7M for Q1 2026 compared to $18.2M in Q1 2025, driven by a 54% YoY decline in R&D expenses to $7.0M, though G&A expenses rose slightly by 4% to $4.7M. Cash and equivalents increased modestly QoQ to $36.6M, but total liquidity (cash + marketable securities) declined 7.6% QoQ to $104.5M amid ongoing cash burn of $8.6M from operations. Stockholders' equity decreased 8% QoQ to $102.5M, reflecting accumulated losses.

• · Net cash provided by investing activities was $10.2M in Q1 2026, compared to $3.4M in Q1 2025, primarily from sales and maturities of marketable securities.
• · Accumulated deficit increased to $357.0M as of March 31, 2026 from $346.3M at December 31, 2025.
• · Stock-based compensation expense was $1.8M in Q1 2026, up from $1.5M in Q1 2025.

12-05-2026

Xilio Therapeutics reported Q1 2026 revenue of $12,648 thousand, a 332% YoY increase from $2,930 thousand, primarily from collaboration and license agreements with partners like Gilead and AbbVie. However, research and development expenses rose 140% YoY to $19,832 thousand while general and administrative expenses declined 19% to $6,928 thousand, resulting in a slightly wider operating loss of $14,112 thousand versus $13,851 thousand prior year; net loss improved to $9,529 thousand from $13,265 thousand due to $4,583 thousand in other income. Cash and cash equivalents increased to $150,333 thousand as of March 31, 2026 from $137,531 thousand at December 31, 2025, supported by $37,256 thousand in financing proceeds, though operating cash use was $22,343 thousand.

• · Deferred revenue decreased to $48,010 thousand as of March 31, 2026 from $60,658 thousand at December 31, 2025.
• · Common stock warrant liabilities decreased to $26,260 thousand from $29,560 thousand QoQ.
• · Stockholders’ equity increased to $72,545 thousand from $35,273 thousand QoQ, driven by $37,256 thousand from prefunded warrants issuance.

12-05-2026

For the three months ended March 31, 2026, Coya Therapeutics reported collaboration revenue of $251,147, down 2.7% YoY from $257,884, while net loss narrowed slightly to $7,206,990 from $7,306,757 amid a 21.4% reduction in R&D expenses to $4,096,580; however, G&A expenses increased 39.4% to $3,781,977. Cash and cash equivalents rose to $50,724,643 from $46,822,786 at December 31, 2025, supported by $10,995,387 net proceeds from a private placement of common stock, though net cash used in operating activities widened to $6,208,530 from $2,828,275 YoY. Total assets stood at $53,271,099 with stockholders' equity at $48,970,360.

• · In-process research and development expense of $10,000 and purchase of $885,000 in investing activities during Q1 2026.
• · Deferred collaboration revenue ending balance of $1,996,833 as of March 31, 2026.
• · Weighted-average shares outstanding: 22,644,304 for Q1 2026 vs 16,720,511 for Q1 2025.
• · Net loss per share: ($0.32) basic and diluted for Q1 2026 vs ($0.44) for Q1 2025.

12-05-2026

Imunon, Inc. reported a net loss of $4.2M for Q1 2026, widening 3.6% YoY from $4.1M, driven by higher R&D expenses up 7.9% while G&A remained flat; loss per share improved to $(0.84) from $(3.15) due to share dilution. Cash and equivalents fell 45% QoQ to $4.8M from $8.8M amid $4.0M operating cash burn (up 40% YoY), though up from $2.9M at Q1 2025 end. Total assets declined to $8.0M from $12.3M, with plans to cut spending and seek funding signaling liquidity pressures.

• · Investment income increased to $57,530 from $42,804 YoY.
• · Operating lease right-of-use assets at $887,892 as of March 31, 2026.
• · Plans include reducing expenditures, pursuing equity/debt funding, partnerships, and out-licensing drug candidates.
• · No purchases of property and equipment in Q1 2026 vs $259,652 in Q1 2025.

12-05-2026

Vishay Precision Group reported net revenues of $84,353, up 17.6% YoY from $71,741, driven by gross profit growth of 21.6% to $32,874. However, selling, general, and administrative expenses increased 20.1% to $32,085, resulting in only slim operating income of $340 versus a prior-year loss of $60, a net loss of $287 (improved from $955), and negative operating cash flow of $596 compared to $5,249 provided last year.

• · Cash and cash equivalents decreased QoQ to $82,486 from $87,366.
• · Capital expenditures increased to $3,060 from $1,507 YoY.
• · Foreign currency translation adjustment contributed to $1,806 other comprehensive loss.
• · Total equity declined to $334,477 from $336,227 QoQ.

12-05-2026

Sharing Economy International Inc. reported zero revenues for Q1 2026, resulting in a net loss of $97,330, significantly wider than the $5,224 loss in Q1 2025, driven by operating expenses rising to $89,955 from $5,224. Cash and cash equivalents declined 58% quarter-over-quarter to $111,273 from $263,147, with operating cash used at $126,432. Total assets edged down to $18,163,567 from $18,320,261, while stockholders' equity decreased to $13,962,119 from $14,059,449.

• · Due from related parties represents 99% of total assets at $18,046,943 as of March 31, 2026.
• · Convertible note payable at $1,430,065 net of discount.
• · No interest or taxes paid during the period.

12-05-2026

Magnolia Bancorp, Inc. reported a widened net loss of $69 thousand for the three months ended March 31, 2026, compared to $30 thousand in the prior year period, driven by noninterest expenses rising 11% YoY to $417 thousand, with salaries and employee benefits up 22% to $230 thousand. However, net interest income increased 3% YoY to $340 thousand, total assets edged up 0.4% QoQ to $37.6 million, and cash equivalents grew 14% QoQ to $5.1 million. Loans receivable net remained relatively flat, declining 1% QoQ to $30.4 million.

• · Loss per share basic and diluted: ($0.09) for Q1 2026 vs ($0.04) for Q1 2025.
• · Weighted average shares outstanding: 768,821 for Q1 2026 vs 767,328 for Q1 2025.
• · Repurchased 1,462 common shares in Q1 2026.
• · ESOP unearned compensation: 63,921 shares as of March 31, 2026.

12-05-2026

Total net revenues rose 9.6% YoY to $426,887 thousand in Q1 2026 from $389,573 thousand, driven by 11.4% growth in North America equipment sales to $267,142 thousand and 16.1% in international service parts to $12,678 thousand. However, North America service parts grew only 0.5% to $31,722 thousand, while international equipment financing declined 17.6% to $75 thousand and other international revenues fell 19.3% to $1,209 thousand. Securitized portfolios showed low delinquency levels with minimal current period gross charge-offs.

• · Foreign exchange gains on intercompany loans of $6,475 thousand in Q1 2026 vs losses of $6,065 thousand in Q1 2025.
• · Securitized current period gross charge-offs: $816 thousand in Q1 2026 (across years shown).
• · Unsecuritized allowance for equipment financing receivables: $830 thousand at March 31, 2026.
• · Company's residual interest in securitized accounts receivable: $36,334 thousand at March 31, 2026 (up from $28,797 thousand at Dec 31, 2025).

12-05-2026

CB Financial Services, Inc. (CBFV) reported robust Q1 2026 net income of $3,867 thousand, more than doubling YoY from $1,909 thousand (+103%), fueled by net interest income growth to $13,872 thousand (+23% YoY) and lower interest expense. Total assets expanded 2.3% QoQ to $1,583,292 thousand, with deposits rising 2.7% QoQ to $1,375,437 thousand. However, net loans declined 0.4% QoQ to $1,147,534 thousand, provisions for credit losses on loans increased to $228 thousand from $68 thousand YoY, and comprehensive income fell to $2,364 thousand from $3,774 thousand YoY due to unrealized securities losses.

• · Provision for credit losses on loans increased to $228 thousand in Q1 2026 from $68 thousand in Q1 2025.
• · Dividends paid at $0.28 per share in Q1 2026 (vs $0.25 in Q1 2025), totaling $1,411 thousand.
• · Treasury stock purchased: 8,553 shares for $292 thousand in Q1 2026.
• · Weighted average basic shares outstanding: 5,053,586 in Q1 2026 (down from 5,125,577 in Q1 2025).
• · Net cash used in investing activities: $13,432 thousand in Q1 2026 (vs provided $13,181 thousand in Q1 2025).

12-05-2026

CERES ORION L.P. reported net income of $12,483,446 for the three months ended March 31, 2026, a strong turnaround from a $4,073,698 loss in the prior year period, driven by trading results of $13,190,874 versus a $3,756,100 loss YoY; total partners’ capital (NAV) increased to $236,315,680 from $231,783,151 QoQ (+2.0%). However, total investment income declined 21% YoY to $1,747,531, net investment loss widened to $(707,428), and net redemptions led to fewer Class A units outstanding (64,969.4048 vs 67,166.3208 QoQ). Total returns were 5.3% for Class A and 5.5% for Class Z, versus -1.5% and -1.3% YoY.

• · Net unrealized depreciation on open futures contracts: $385,089 (0.17% of NAV) at March 31, 2026 vs net unrealized appreciation of $4,931,940 (2.13% of NAV) at December 31, 2025.
• · Options purchased fair value declined to $1,620,334 (premiums paid $2,184,626) from $4,892,119 (premiums paid $5,814,512) QoQ.
• · SOYBEAN OIL FUTR MAY26 futures sold: fair value $(4,908,432) (-2.08% of NAV) at March 31, 2026.

12-05-2026

Ceres Classic L.P. reported total assets of $140,023,784 and partners' capital (NAV) of $138,888,369 as of March 31, 2026, up 8.5% and 9.4% respectively QoQ from December 31, 2025, driven by net income of $13,824,257 primarily from $14.1M in trading results. However, interest income declined 22% YoY to $1,003,580, net investment income swung to a ($279,609) loss from a $40,095 gain, and net unrealized appreciation on futures and forwards decreased QoQ to $1,473,147 and $1,037,556 respectively. Class A NAV per unit rose 10.9% QoQ to $32.21, while redemptions reduced Class A units by 63,218 QoQ.

• · Class A NAV per unit: $32.21 (March 31, 2026) vs $29.04 (Dec 31, 2025), up 10.9%.
• · Total futures contracts purchased fair value: $369,448 (0.27% of NAV) March 31, 2026.
• · Total futures contracts sold fair value: $1,103,699 (0.79% of NAV) March 31, 2026.
• · Net investment loss: ($279,609) Q1 2026 vs $40,095 gain Q1 2025.
• · Several futures segments show negative fair values e.g. Currencies purchased -(0.29%), Indices -(0.29%) as of March 31, 2026.

12-05-2026

For the quarter ended March 31, 2026, Ceres Tactical Systematic L.P. reported net income of $2,721,003, a turnaround from a $985,726 loss in Q1 2025, driven by $2,838,073 in trading results despite a $117,070 net investment loss and higher total expenses of $463,238 (up from $377,105 YoY). Total partners' capital (NAV) increased 2.1% QoQ to $44,186,923 from $43,284,792, with NAV per unit rising ~6.4% across classes (Class A to $929.08), though offset by net unrealized depreciation of $268,992 on open futures and forward contracts compared to prior appreciation. Redemptions totaled $1,818,872, reducing Class A units outstanding by ~4.3% QoQ.

• · Net unrealized depreciation on open futures contracts: $251,004 as of March 31, 2026 (vs appreciation of $668,526 at Dec 31, 2025)
• · Net unrealized depreciation on open forward contracts: $17,988 as of March 31, 2026 (vs appreciation of $172,829 at Dec 31, 2025)
• · Interest income declined to $346,168 in Q1 2026 from $422,035 in Q1 2025
• · Incentive fees: $94,102 in Q1 2026 (none in Q1 2025)

12-05-2026

Ceres Tactical Commodity L.P. reported net income of $3,719,799 for Q1 2026, down slightly from $3,925,347 in Q1 2025, driven by lower trading results of $3,946,210 versus $4,129,664 despite reduced expenses. Total partners’ capital declined 3.1% QoQ to $96,496,468 from $99,556,199 due to net redemptions of $6,779,530 outweighing subscriptions and income, though NAV per unit rose for Class A (3.8% to $2,651.51) and Class Z (4.0% to $2,229.08) while Class D units were fully redeemed. Total assets fell 5.6% QoQ to $99,513,101 amid net unrealized depreciation on futures of $108,305 versus prior appreciation.

• · Redemptions totaled $6,859,530 in Q1 2026, exceeding subscriptions of $80,000.
• · Equity in related party trading account decreased to $88,439,582 from $92,493,886 QoQ.
• · Total investment income fell 27.5% YoY to $842,996 from $1,163,748.

12-05-2026

Flanigan’s Enterprises reported Q2 FY26 revenues of $56,515, up 5.9% YoY from $53,359, with restaurant food sales growing 6.2% to $34,608 and package store sales up 7.5% to $12,955, while restaurant bar sales increased modestly 2.4% to $8,391. Operating income rose 18.6% to $4,169, driving net income attributable to stockholders of $2,875 (+6.9% YoY). For H1 FY26, revenues grew 5.5% to $109,083 and net income to stockholders surged 34.1% to $3,680, though property and equipment net slightly declined to $81,620 from $82,689 year-end.

• · Cash flows from operating activities for H1 FY26: $7,087 (up 23.8% YoY from $5,729).
• · Total current assets as of March 28, 2026: $34,413 (up from $30,593 at FY start).
• · Deferred revenue as of March 28, 2026: $2,967.
• · Net cash used in investing activities H1 FY26: $1,897.
• · Weighted average shares outstanding: 1,858,647 (unchanged).

12-05-2026

For Q1 2026, Canterbury Park Holding Corp reported total net revenues of $13,509,534, up 2.8% YoY from $13,141,632, driven by strong growth in food and beverage (+13.8%) and other revenues (+12.5%), though casino revenues were nearly flat (+0.5%) and pari-mutuel declined 5.6%. Operating income rose 62.5% to $1,055,699 from $649,671, leading to net income of $169,878 versus a prior-year loss of $299,210. However, operating cash flow dipped slightly to $3,241,387 from $3,374,172.

• · Basic EPS $0.03 in Q1 2026 vs ($0.06) in Q1 2025
• · Cash dividends declared per share $0.07 for both periods
• · Equity investment loss $1,216,794 in Q1 2026 (improved from $1,573,162)
• · Capex additions to land, buildings, equipment $634,974 in Q1 2026

12-05-2026

Qnity Electronics reported Q1 2026 net sales of $1,315M, up 17.6% YoY from $1,118M, driven by growth in Semiconductor Technologies (+12.1% to $722M) and Interconnect Solutions (+25.1% to $593M). However, net income fell 18.6% YoY to $162M from $199M, impacted by higher cost of sales, R&D, SG&A, transformation charges, and new interest expense of $61M, resulting in diluted EPS of $0.72 versus $0.92. Cash provided by operating activities declined to $135M from $207M, with cash and equivalents at $857M.

• · Total assets stable at $14,063M as of March 31, 2026 versus $14,070M at December 31, 2025.
• · Long-term debt at $4,000M as of March 31, 2026.
• · Comprehensive income declined to $109M from $253M YoY, driven by $53M other comprehensive loss mainly from cumulative translation adjustments.
• · Capital expenditures of $122M in Q1 2026, up from $104M YoY.
• · Common stock repurchases of $25M in Q1 2026.

12-05-2026

Broadwind, Inc. reported Q1 2026 revenues of $34,057 thousand, down 7.5% YoY from $36,838 thousand, while gross profit improved 8.5% to $4,693 thousand amid lower cost of sales. Operating income more than doubled to $389 thousand from $184 thousand, but net loss widened to $495 thousand from $370 thousand due to higher interest expense. Operating cash flow swung to a positive $2,905 thousand from a $8,037 thousand outflow YoY, with cash balance rising to $943 thousand at quarter-end.

• · Property and equipment, net increased to $40,899 thousand from $39,464 thousand QoQ.
• · Inventories remained relatively flat at $42,743 thousand vs $42,008 thousand QoQ.
• · Weighted average basic shares outstanding increased to 23,338 thousand from 22,361 thousand YoY.
• · Capex (purchases of property and equipment) rose to $2,778 thousand from $916 thousand YoY.

12-05-2026

Federal Home Loan Bank of Dallas reported net income of $121,877 thousand for Q1 2026, down 19.1% YoY from $150,624 thousand, driven by lower interest income on advances ($530,708 thousand vs. $768,217 thousand) and net trading losses of $9,736 thousand versus gains of $12,524 thousand prior year. Total assets contracted 10.6% QoQ to $97,072,064 thousand from $108,512,015 thousand, primarily due to a 13.0% decline in advances to $44,215,047 thousand, while net interest income fell 9.9% YoY to $171,188 thousand. However, retained earnings increased to $3,307,256 thousand, and total comprehensive income was positive at $122,821 thousand.

• · Provision for credit losses was minimal at $125 thousand in Q1 2026, down from $2,164 thousand YoY.
• · Capital stock Class B-1 shares decreased to 10,303,207 from 12,636,851 QoQ; Class B-2 to 17,224,190 from 20,746,739.
• · Other expense increased 6.4% YoY to $37,272 thousand, driven by higher compensation and voluntary grants.

12-05-2026

Thunder Mountain Gold reported a widened net loss of $590,758 for Q1 2026, up 9.3% YoY from $540,300, driven by sharply higher exploration ($167,128, +149%) and legal/accounting expenses ($95,186, +108%), though management/administrative costs declined 22% to $332,281. Operating cash use surged to $607,786 from $247,613 amid the investment in a $211,324 mineral property acquisition. Despite the net cash decrease of $779,110, the cash balance remained solid at $1,813,057, up significantly from $363,709 YoY.

• · Stock-based compensation expense: $136,320 in Q1 2026 (down from $325,815 YoY)
• · Proceeds from stock options exercised: $40,000 in Q1 2026
• · Subscription receivable recorded: $(50,000) in Q1 2026
• · Mineral properties increased to $211,324 from $0 QoQ
• · Total property and equipment: $803,969 at March 31, 2026 (up from $592,645 at Dec 31, 2025)
• · Principal payments scheduled: $37,100 in 2026 rising to $45,095 in 2030, totaling $205,000

12-05-2026

For Q1 2026 ended March 31, Hoyne Bancorp reported a net loss of $118,352, an improvement from $166,035 in Q1 2025, supported by net interest income growth of 39.6% YoY to $4,204,499 from stronger loan interest income. However, noninterest expenses increased 32.3% YoY to $4,522,916, total assets declined 2.5% QoQ to $477,221,986, deposits fell 2.9% QoQ to $311,985,430, and cash equivalents dropped sharply 71.6% QoQ to $13,489,530. Loans receivable grew 7.7% QoQ to $288,635,189, but comprehensive loss was $375,793.

• · Provision for credit losses remained flat at $135,000 for Q1 2026 vs Q1 2025.
• · Allowance for credit losses $2,816,819 as of March 31, 2026 (up from $2,681,819 at Dec 31, 2025).
• · Investment securities AFS declined to $103,699,246 from $106,653,763 QoQ.
• · Bank-owned life insurance increased to $20,133,252 from $14,948,941 QoQ due to $5M purchase.

12-05-2026

Muzero Acquisition Corp reported net income of $921,491 for the three months ended March 31, 2026, driven by $1,126,721 in interest income primarily from the Trust Account following its IPO, which funded $202,374,142 in investments held in Trust. However, the company recorded an operating loss of $205,230, and shareholders' deficit widened to $(6,008,384) from $(24,541) due to accretion of Class A shares to redemption value. Total assets grew significantly to $203,574,958 from $198,950, reflecting IPO proceeds, while cash and equivalents increased to $934,577 from $69.

• · Promissory Note – related party repaid to $0 from $145,000.
• · Advances from related party: $9,450 as of March 31, 2026.
• · Basic and diluted net income per share: $0.05 for both Class A redeemable and Class B non-redeemable ordinary shares.
• · Net cash used in operating activities: $(370,758).
• · Non-cash: Offering costs included in accrued offering costs $75,000; Deferred Fee payable $7,043,750.

12-05-2026

BayFirst Financial Corp. reported a net loss of $5,680 thousand for Q1 2026, widening significantly from $335 thousand in Q1 2025, driven by a 90% drop in noninterest income to $884 thousand (primarily no repeat of $7,327 thousand gain on government guaranteed loan sales) and 14% decline in net interest income to $9,449 thousand. Total assets decreased 8% quarter-over-quarter to $1,195,910 thousand, with net loans HFI down 3% to $857,987 thousand and total deposits falling 8% to $1,085,869 thousand. Positively, provision for credit losses declined 30% YoY to $3,078 thousand and noninterest expense fell 6% to $14,886 thousand.

• · Basic and diluted loss per common share of $(1.48) in Q1 2026 vs $(0.17) in Q1 2025.
• · Shareholders’ equity declined to $81,867 thousand from $87,569 thousand QoQ.
• · Net cash used in operating activities of $3,206 thousand in Q1 2026 vs provided $74,164 thousand in Q1 2025.

12-05-2026

CreditRiskMonitor.com, Inc. reported Q1 2026 operating revenues of $4,986,878, up 2.4% YoY from $4,871,412, driven by steady subscription revenue. However, higher data and product costs ($2,520,905, +10.4% YoY) and SG&A expenses led to an operating loss of $93,727, compared to a $25,367 profit in Q1 2025, resulting in net income of $58,312, down 63.3% YoY. Total assets declined to $25,149,169 from $26,237,315 QoQ, with cash and equivalents at $5,715,460, down from $6,248,223.

• · Net cash used in operating activities improved to $452,056 from $837,587 YoY.
• · Held-to-maturity securities totaled $12,651,204 at Mar 31 2026 (Level 2 fair value).
• · Unexpired subscription revenue (current) decreased to $10,755,411 from $10,933,761 QoQ.
• · Weighted average diluted shares: 10,847,137 in Q1 2026 vs 10,831,979 in Q1 2025.

12-05-2026

Brightwood Capital Corp I reported a net increase in net assets resulting from operations of $18,621 for Q1 2026, up 53.7% YoY from $12,118, driven by net investment income of $13,723 (up 5.7% YoY) and realized/unrealized gains of $4,898. However, total investment income declined 1.1% YoY to $22,777 while expenses fell 10.7% to $8,972. Total net assets rose 5.2% QoQ to $421,709 with NAV per share at $10.33 (up 4.7% QoQ), but were down 1.0% YoY from $425,961.

• · Cash and cash equivalents increased to $40,976 from $23,070 QoQ.
• · Line of credit payable rose to $450,560 from $412,060 QoQ.
• · Healthcare sector investments at fair value: $160,165 (38.0% of net assets).
• · Technology & Telecommunications sector investments at fair value: $160,617 (38.1% of net assets).
• · Transportation & Logistics sector investments at fair value: $241,215 (56.9% of net assets).

12-05-2026

For the three months ended March 31, 2026, Manulife Private Credit Fund reported total investment income of $7,535,177, up 70.6% YoY from $4,417,886, driven by higher interest income, with net investment income rising 57.9% YoY to $3,930,532. However, a net unrealized depreciation of $1,120,413 resulted in nearly flat increase in net assets from operations at $2,875,935 (-0.4% YoY), while net assets declined 0.7% QoQ to $169,592,882 and NAV per share fell to $20.54 from $20.68.

• · Credit facility payable increased to $145,700,000 from $141,500,000 QoQ.
• · Cash distributions paid $4,190,114 in Q1 2026, up from $3,179,815 YoY.
• · Net cash used in operating activities improved to $(62,409) from $(22,759,249) YoY.
• · Unrealized depreciation on senior loans $1,097,841 in Q1 2026.